The Anti-Tumor Effects and Molecular Mechanisms of Suberoylanilide Hydroxamic Acid (SAHA) on the Aggressive Phenotypes of Ovarian Carcinoma Cells

SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin

(2012) Jong-Shiaw Jin et al.   PATHOLOGY & ONCOLOGY RESEARCH

Cdc2: a monopotent or pluripotent CDK?

(2011) X. Hu et al.   CELL PROLIFERATION

Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells

(2011) Praveen Rajendran et al.   Clinical Epigenetics

Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines

(2010) Adriano Angelucci et al.   GYNECOLOGIC ONCOLOGY

Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids

(2009) Valérie Lobjois et al.   EUROPEAN JOURNAL OF CANCER

Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines

(2009) Charles S. Dietrich et al.   GYNECOLOGIC ONCOLOGY

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

(2008) Susan C. Modesitt et al.   GYNECOLOGIC ONCOLOGY

Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs

(2008) Degui Wang et al.   INTERNATIONAL JOURNAL OF UROLOGY

Prognostic role of global DNA-methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens

(2008) D. Minardi et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Histone deacetylase inhibitor SAHA induces ERα degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling

(2007) Xin Yi et al.   BIOCHEMICAL PHARMACOLOGY